0

The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma

Maria Del Castillo, Fabian A Romero, Esther Argüello, Chrisann Kyi, Michael A Postow, Gil Redelman-Sidi

Clin Infect Dis. 2016 Dec 1;63(11):1490-1493.

PMID: 27501841

Abstract:

The risk of infection among patients receiving immune checkpoint blockade is unknown. We retrospectively reviewed medical records of 740 patients with melanoma who received immune checkpoint blockers. Serious infection occurred in 54 patients (7.3%). The main risk factors were receipt of corticosteroids and/or infliximab.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
IAR424662 Phalloidin-Atto 740 Phalloidin-Atto 740 Price
qrcode